# TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

> **NCT00386412** · PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 132 (estimated)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT00386412
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2009-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386412, "TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00386412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*